Latest Regulatory News

Phoslock Environmental Technologies has amended its December 2025 quarterly report to correct funding data and withdraw its sales outlook, while reporting improved cash flow and resuming factory operations.

Alice Queen Limited (AQX) has had its trading suspension lifted immediately following its response to an ASX Price Query, reopening access for investors.

Arena REIT has announced an ordinary quarterly dividend of AUD 0.048125 per security, payable on 5 February 2026, alongside a Dividend Reinvestment Plan priced at AUD 3.50330, offering investors a 1.5% discount.

DXN Limited has signed a strategic MOU with Super Sistem Indonesia to form a joint venture targeting Indonesia’s rapidly expanding digital infrastructure market, aiming for US$7 million in revenue over three years.

Mesoblast has received encouraging feedback from the FDA on its cell therapy rexlemestrocel-L, showing meaningful pain relief and potential opioid use reduction in chronic low back pain patients. The company’s ongoing Phase 3 trial aims to confirm these benefits and advance regulatory approval.

Nickel Industries faced a challenging December quarter due to delayed regulatory approvals impacting ore sales, yet the company kicked off 2026 with robust nickel ore sales and record earnings from its HPAL project.

Riversgold Limited reports encouraging shallow gold intersections at its Northern Zone Gold Project near Kalgoorlie, supported by a $2.15 million capital raise with MEGA Resources as a key investor. The drilling results and strategic partnership set the stage for advancing mining plans in 2026.

Jupiter Energy reported steady oil production and US$1.6 million in domestic sales for Q4 2025, while completing integration of its West Zhetybai oilfield into a regional gas utilisation network.

MRG Metals has completed its acquisition of the Garies Rare Earth Project, adding a high-grade, magnet-rich rare earth asset in South Africa to its portfolio. This move significantly boosts the company’s exposure to critical minerals essential for emerging technologies.

Neuren Pharmaceuticals has affirmed the material impact of Acadia’s projection that DAYBUE global net sales could reach approximately US$700 million by 2028, underpinning its royalty revenue outlook.

Phoslock Environmental Technologies has reversed its cashflow deficits with a quarterly surplus, resumed factory operations after a long pause, and is gearing up for significant sales growth in 2026.

Orthocell Limited has reported a record $3.2 million revenue for the December 2025 quarter, marking its seventh consecutive quarter of growth, fuelled by expanding sales of its nerve repair product Remplir in the US and other international markets.